AbbVie (ABBV) Change in Cash (2012 - 2026)
AbbVie (ABBV) reported Change in Cash of $4.2 billion for Q1 2026, up 1292.55% year-over-year from $298.9 million in Q1 2025, and up 1140.5% on a QoQ basis from -$400.0 million in Q4 2025.
AbbVie (ABBV) has 15 years of Change in Cash data on file, last reported at $4.2 billion in Q1 2026.
- Quarterly Change in Cash rose 1292.55% year-over-year to $4.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (up 132.7% YoY) and the FY2025 annual result came in at -$295.0 million, up 95.95% from the prior year.
- Change in Cash climbed to $4.2 billion in Q1 2026 per ABBV's latest filing, from -$400.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $5.3 billion in Q1 2024 and bottomed at -$5.9 billion in Q3 2024.
- The 5-year median for Change in Cash is -$400.0 million (2025), against an average of -$20.9 million.
- The widest annual swing landed in 2022, when Change in Cash tumbled 379.33%; it then jumped 1292.55% in 2026.
- Tracing ABBV's Change in Cash over 5 years: stood at -$2.6 billion in 2022, then surged by 82.02% to -$473.0 million in 2023, then plunged by 266.38% to -$1.7 billion in 2024, then jumped by 76.92% to -$400.0 million in 2025, then jumped by 1140.5% to $4.2 billion in 2026.
- Per Business Quant, the three latest ABBV Change in Cash figures stand at $4.2 billion (Q1 2026), -$400.0 million (Q4 2025), and -$838.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.16 Bn |
| Dec 31, 2025 | -400.00 Mn |
| Sep 30, 2025 | -838.00 Mn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | -349.00 Mn |
| Dec 31, 2024 | -1.73 Bn |
| Sep 30, 2024 | -5.87 Bn |
| Jun 30, 2024 | -4.94 Bn |
| Mar 31, 2024 | 5.25 Bn |
| Dec 31, 2023 | -473.00 Mn |
| Sep 30, 2023 | 4.53 Bn |
| Jun 30, 2023 | 2.05 Bn |
| Mar 31, 2023 | -2.49 Bn |
| Dec 31, 2022 | -2.63 Bn |
| Sep 30, 2022 | 3.31 Bn |
| Jun 30, 2022 | 2.42 Bn |
| Mar 31, 2022 | -3.65 Bn |
| Dec 31, 2021 | -2.44 Bn |
| Sep 30, 2021 | 3.64 Bn |
| Jun 30, 2021 | -1.21 Bn |
| Mar 31, 2021 | 1.31 Bn |
| Dec 31, 2020 | 559.00 Mn |
| Sep 30, 2020 | 1.87 Bn |
| Jun 30, 2020 | -35.13 Bn |
| Mar 31, 2020 | 1.22 Bn |
| Dec 31, 2019 | 29.28 Bn |
| Sep 30, 2019 | 5.48 Bn |
| Jun 30, 2019 | 275.00 Mn |
| Mar 31, 2019 | -2.39 Bn |
| Dec 31, 2018 | -726.00 Mn |
| Sep 30, 2018 | 4.47 Bn |
| Jun 30, 2018 | -5.46 Bn |
| Mar 31, 2018 | -296.00 Mn |
| Dec 31, 2017 | 857.00 Mn |
| Sep 30, 2017 | 2.36 Bn |
| Jun 30, 2017 | 1.35 Bn |
| Mar 31, 2017 | -360.00 Mn |
| Dec 31, 2016 | -1.12 Bn |
| Sep 30, 2016 | -109.00 Mn |
| Jun 30, 2016 | -1.23 Bn |
| Mar 31, 2016 | -843.00 Mn |
| Dec 31, 2015 | -824.00 Mn |
| Sep 30, 2015 | 1.82 Bn |
| Jun 30, 2015 | -506.00 Mn |
| Mar 31, 2015 | -442.00 Mn |
| Dec 31, 2014 | 629.00 Mn |
| Sep 30, 2014 | -1.37 Bn |
| Jun 30, 2014 | 946.00 Mn |
| Mar 31, 2014 | -1.46 Bn |
| Dec 31, 2013 | 620.00 Mn |
| Sep 30, 2013 | 232.00 Mn |
| Jun 30, 2013 | 1.76 Bn |
| Mar 31, 2013 | 1.08 Bn |
| Dec 31, 2012 | 3.14 Bn |
| Sep 30, 2012 | 2.69 Bn |
| Jun 30, 2012 | 33.00 Mn |
| Mar 31, 2012 | 14.00 Mn |